Breakthrough T1D, formerly JDRF, is grateful that Congress and the President enacted a six-month, $80 million extension of the Special Diabetes Program (SDP), a crucial program that contributes millions of dollars to type 1 diabetes (T1D) research annually through the National Institutes of Health.
“We deeply appreciate our Breakthrough T1D champions who have continued to support and push for renewal of the Special Diabetes Program and the critical funding it provides for type 1 diabetes research,” said Breakthrough T1D Chief Global Advocacy Officer Lynn Starr. “We’d especially like to thank Senate Diabetes Caucus co-chairs, Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), and Congressional Diabetes Caucus co-chairs, Representatives Diana DeGette (D-CO) and Gus Bilirakis (R-FL), for their leadership and commitment to improving the lives of Americans affected by type 1 diabetes.”
The SDP has led to significant T1D advances, including automated insulin delivery systems, the first FDA-approved therapy that can delay the onset of T1D, progress toward beta cell replacement therapies, improvements to continuous glucose monitors, and treatments for T1D complications like diabetic retinopathy.
We will continue to work with our champions as we pursue a longer-term renewal of the program.
